Efficacy and safety of PEG-IFN α-2b and tenofovir amibufenamide in combination therapy for chronic hepatitis B
PEG-IFN α-2b and TMF combination therapy effectively reduced HBsAg levels in CHB patients. Baseline HBsAg levels and the magnitude of their decline by week 24 served as robust predictors of serological response, exhibiting high diagnostic value.
Authors
- Shihui Liu (ORCID: https://orcid.org/0000-0002-4406-4183)
- L. Li
- Dongdong Li (ORCID: https://orcid.org/0009-0005-5133-4478)
- Chuanmiao Liu (ORCID: https://orcid.org/0000-0002-7766-2091)
- Yi Luo (ORCID: https://orcid.org/0000-0003-0007-0394)
- Wenjie Zhang (ORCID: https://orcid.org/0000-0002-0773-3093)
- Xiaojun Liu (ORCID: https://orcid.org/0000-0003-3399-3486)
- Wen Zhao (ORCID: https://orcid.org/0000-0001-8856-7113)
- Yufeng Gao (ORCID: https://orcid.org/0000-0003-0032-3531)
- Zonghao Zhao
Institutions
- University of Science and Technology of China (CN)
- Bengbu Medical College (CN)
- Anhui Medical University (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- Institute of Infection and Immunity (CA)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1186/s12879-025-12296-1
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00